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Background: According to the modified amyloid hypothesis the main event in the pathogenesis of Alzheimer’s
disease (AD) is the deposition of neurotoxic amyloid β-peptide (Aβ) within neurons. Additionally to full-length peptides,
a great diversity of N-truncated Aβ variants is derived from the larger amyloid precursor protein (APP). Vast evidence
suggests that Aβx-42 isoforms play an important role triggering neurodegeneration due to its high abundance,
amyloidogenic propensity and toxicity. Although N-truncated and Aβx-42 species have been pointed as crucial players
in AD etiology, the Aβ5-x isoforms have not received much attention.
Results: The present study is the first to show immunohistochemical evidence of Aβ5-x in familial cases of AD (FAD)
and its distribution in APP/PS1KI, 5XFAD and 3xTG transgenic mouse models. In order to probe Aβ5-x peptides we
generated the AB5-3 antibody. Positive plaques and congophilic amyloid angiopathy (CAA) were observed among all
the FAD cases tested carrying either APP or presenilin 1 (PS1) mutations and most of the sporadic cases of AD (SAD).
Different patterns of Aβ5-x distribution were found in the mouse models carrying different combinations of autosomal
mutations in the APP, PS1 and Tau genes. All of them showed extracellular Aβ deposits but none CAA. Additionally,
they were all affected by a severe amyloid pathology in the hippocampus among other areas. Interestingly, neither
5XFAD nor APP/PS1KI showed any evidence for intraneuronal Aβ5-x.
Conclusions: Different degrees of Aβ5-x accumulations can be found in the transgenic AD mouse models and human
cases expressing the sporadic or the familial form of the disease. Due to the lack of intracellular Aβ5-x, these isoforms
might not be contributing to early mechanisms in the cascade of events triggering AD pathology. Brain sections
obtained from SAD cases showed higher Aβ5-x–immunoreactivity in vascular deposits than in extracellular plaques,
while both are equally important in the FAD cases. The difference may rely on alternative mechanisms involving Aβ5-x
peptides and operating in a divergent way in the late and early onset forms of the disease.
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Alzheimer’s disease (AD) is the most common type of de-
mentia worldwide. It is characterized by the accumulation
of specific proteins, namely tau and amyloid-beta protein
(Aβ). In fact, these proteins are essential to confirm an AD
diagnosis, given that the two major histopathological hall-
marks are extracellular amyloid-β plaques surrounded by* Correspondence: tbayer@gwdg.de
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unless otherwise stated.dystrophic neurites and intracellular neurofibrillary tan-
gles. Furthermore, AD is characterized by neuronal loss,
gliosis and congophilic angiopathy mainly affecting the
cortex and the hippocampal formation [1].
The amyloid hypothesis considers the accumulation of
Aβ peptides as the central and triggering event in AD
[2,3]. The formation of neurotoxic oligomers and larger
assemblies of Aβ are thought to be the product of an im-
balance in its production and clearance [4]. Aβ derives
from the larger amyloid precursor protein (APP) by pro-
teolytic cleavage of different secretase enzymes. Thel Ltd. This is an Open Access article distributed under the terms of the Creative
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Aβ peptides of various lengths [5]. The γ-secretase com-
prises a high molecular weight complex that depends on
presenilin-1 and −2 (PS1, PS2) activity to cleave within the
transmembrane domain of APP to generate Aβ peptides
and is composed of four integral membrane proteins: pre-
senilin, nicastrin, Aph-1 and Pen-2 [6]. Supporting the
amyloid hypothesis, autosomal dominant mutations in
APP, PS1 and PS2 genes cause familial early onset AD
mainly by increasing the production of Aβx-42 [7]. How-
ever, advancing in age is considered the most prevalent risk
factor for Aβ accumulation and most of the cases have a
late onset. These cases are classified as sporadic AD.
Extracellular plaques are formed by Aβ peptides with
different C–termini ranging from position 38 to 43 [5].
Since the 42 amino acid isoforms Aβx-42 are highly sus-
ceptible to aggregate and to form oligomer and amyloid
fibrils [8], it is considered the main plaque component
and the initiator of plaque formation in AD pathogenesis
[9]. In addition to the most prevalent species Aβx-40 and
Aβx-42, other isoforms such as Aβx-38 has been reported
in different mouse models, FAD cases due to mutations
in APP and PS1 and in the vascular Aβ deposits of SAD
cases [10,11]. Aβ species ending at position 43 have
shown to be potently amyloidogenic and abundant [12].
Additionally to the full length Aβ peptides starting with
N-terminal aspartate at position 1, different N-truncated
isoforms have been demonstrated to be as abundant as
toxic due to their capacity to rapidly form stable aggre-
gates [13]. Not much is known about the N-terminally
truncated Aβ5-x present in the amyloid pathology of AD
brains. It has been suggested that these Aβ variants are
preferentially formed by an alternative cleavage of APP
involving caspase activity [14].
The aim of the present work was to characterize our
recently generated antibody as a tool to study the pres-
ence of Aβ5-x in different AD transgenic mouse models
and human cases, including sporadic AD and familial
AD cases carrying either APP or PS1 mutations.
Material and methods
Antibodies
The rabbit polyclonal antibodies AB5-3 and 24311 were
generated by PSL Heidelberg (will be distributed by T.A.B.
upon request). 24311 recognizes pan-Aβ (epitope Aβ4–40)
and AB5-3 recognizes the free N-terminus of Aβ5–42 (epi-
tope Aβ5–42). The polyclonal rabbit antibody Aβ42 was
purchase from Synaptic Systems, Goettingen. The mono-
clonal antibody 4G8 is a pan-Aβ antibody (epitope 17–24;
Covance). All antibodies were affinity purified.
Human brain samples
We examined the brains of 12 sporadic AD and 9 non-
demented control patients (Table 1). In addition, westudied brains from familial AD patients either carrying
APP or PS1 mutations. The APP mutations KM670/
671NL (Swedish) [15] and E693G (Arctic) [16,17] were
included as well as three different subjects carrying the
PS1 delta exon 9 mutation [18]. Human brain samples
were obtained from the Netherlands Brain Bank (NBB),
Hopital de la Salpetriere (a generous gift of C. Duyckaerts
and V. Sazdovitch), University Hospital Helsinki and from
Uppsala University. Definite diagnosis was based on estab-
lished criteria and written informed consent was obtained
from all subjects.
Transgenic mouse brain samples
Brain sections were obtained from 3 established AD trans-
genic mouse models including 3xTg [19], APP/PS1KI [20]
(generous gift by Dr. Laurent Pradier, Sanofi) and 5XFAD
[21]. The 5XFAD mice have been crossed on C57Bl6 back-
ground [22].
Sample preparation
The amyloid β (Aβ) variants Aβ1–40, Aβ1–42, Aβ4–38,
Aβ4–40, Aβ4–40, Aβ5–42, AβpE3–40, and AβpE3–42 were
purchased from Peptide Specialty Laboratory (PSL,
Heidelberg) and used without further purification as previ-
ously described [23]. Briefly, Aβ peptides were dissolved in
10 mM NaOH at a concentration of 1 mg/mL and ali-
quoted in 50 μl volumes. After flash freezing in liquid ni-
trogen, the aliquots were stored at −80°C until use.
Analysis of AB5-3 using dot blotting
2 μl of different Aβ isoforms were spotted on a nitrocellu-
lose membrane in different quantities (2, 1, 0.5, 0.25 and
0.125 μg). The membrane was dried for 20 minutes and
blocked with 10% non-fat dry milk in TBS-T (10 mM Tris
pH 8.0, 150 mM NaCl, 0.05% Tween 20) for 30 minutes.
Primary antibodies AB5-3 (diluted 1:500) and 24311 (pan-
Aβ, 1:500 were incubated overnight at 4°C. Running and
transfer buffers were applied according to the manufac-
turer. The blots were developed using enhanced chemilu-
minescence according to the manufacturer (Roth). Horse
radish conjugated swine anti-rabbit antibody was used as a
secondary antibody (1:3,000, Dianova).
Electrophoresis and Western blotting of synthetic peptides
For Western blot analysis under reducing conditions,
2 μg of each Aβ peptide was loaded per lane after heat-
ing at 95°C for 5 minutes on 4 - 12% Tris-Tricin Vario-
Gels (Anamed), transferred to 0.45 μm nitrocellulose
membranes (GE Healthcare) and detected using the pri-
mary antibodies AB5-3 (diluted 1:500) and 4G8 (diluted
1:2000). Running and transfer buffers were applied ac-
cording to the manufacturer. The blots were developed
using enhanced chemiluminescence according to the
manufacturer (Roth).
Table 1 Demographic data and semiquantitative analysis of antibody stainings in SAD, FAD and non-demented
control cases
Case Age Gender Braak stage Aβ5-x Aβ
SP CAA SP CAA
Sporadic AD cases:
AD-1 88 F IV + - +++ ++
AD-2 84 F IV + - +++ -
AD-3 86 M IV + ++ ++ +++
AD-4 88 F IV + - ++ -
AD-5 84 F IV + ++ +++ ++
AD-6 93 M IV - + ++ +++
AD-7 92 M IV - + +++ ++
AD-8 92 F IV + ++ +++ +++
AD-9 91 F IV + ++ +++ +++
AD-10 91 M IV + + ++ +++
AD-11 92 F IV - + ++ +++
AD-12 91 F IV - - +++ ++
Non-demented control cases:
NDC-1 70 M 0 - - - -
NDC-2 90 F I + + ++ ++
NDC-3 88 F I + - ++ -
NDC-4 73 M 0 - - - -
NDC-5 91 M I - - - -
NDC-6 78 F I + - ++ -
NDC-7 84 M I - - - -
NDC-8 78 M I + - ++ ++
NDC-9 82 F I - - - -
Familial AD cases
APPE693G 64 M n.a. ++ ++ +++ +++
APPKM670/671NL 61 F n.a. ++ ++ +++ +++
PS1ΔEx9 69 M n.a. ++ + +++ +
PS1ΔEx9 61 M n.a. ++ ++ +++ +
PS1ΔEx9 64 M n.a. + + +++ +
Abbreviations: SP senile plaques, CAA congophilic amyloid angiopathy.
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Immunohistochemistry was performed on 4 μm sagittal
paraffin sections, as described previously [23]. In brief, sec-
tions were deparaffinized in xylene, followed by rehydration
in a series of ethanol (70%, 95%, and 100%). After treatment
with 0.3% H2O2 in 0.01 M PBS to block endogenous perox-
idases, sections were boiled in 0.01 M citrate buffer pH 6.0
for antigen retrieval, followed by 3 min incubation in 88%
formic acid. Non-specific binding sites were blocked by
treatment with skim milk and fetal calf serum in PBS for
1 h at room temperature (RT), prior to the addition of the
primary antibodies. Rabbit polyclonal antibodies against
Aβ5-x (1:100, AB5-3) and Aβ42 (1:500, Synaptic Systems,
Goettingen, Germany), as well as mouse monoclonal 4G8(1:5000, Covance, Dedham, MA, USA) and the rabbit poly-
clonal 24311 (1:500, [23]) pan-Aβ antibodies were incu-
bated overnight in a humid chamber at RT. This was
followed by incubation with the corresponding biotinylated
secondary antibodies (1:200, DAKO, Glostrup, Denmark)
at 37°C before visualization of the staining using the
ABC method with a Vectastain kit (Vector Laboratories,
Burlingame, USA) and diaminobenzidine (DAB) as chro-
mogen. Counterstaining was carried out with hematoxylin.
Results
Antibody specificity
The specificity of the polyclonal rabbit antibody AB5-3
was tested by dot blot (Figure 1) and western blot analysis
Figure 1 Analysis of the AB5-3 using dot blotting. Full length and N-truncated amyloid-β peptides were probed and spotted into a nitrocellulose
membrane. (A) After incubation with the primary antibody AB5-3 only the Aβ5–42 variant was recognized indicating specificity for this peptide. (B) The
pan-Aβ antibody 24311 recognized all Aβ variants demonstrating that all peptides were available.
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length peptides starting with aspartate at position 1 and
other N-truncated Aβ isoforms starting with pyrogluta-
mate at position 3 or phenylalanine at position 4. Under
denaturing conditions AB5-3 reacted only with Aβ5–42,
thus detecting ragged peptides starting with arginine at
position 5. Data obtained by western blot indicates thatFigure 2 SDS-PAGE Western blot analysis of the AB5-3 and pan-Aβ 4G
probed to a membrane. (A) The polyclonal AB5-3 antibody detects Aβ5–42 tr
detects different sizes of all Aβ species.AB5-3 is binding to low molecular weight forms of the
peptide detecting only soluble Aβ5–42 trimers and tetra-
mers (Figure 2).
Aβ5-x in sporadic Alzheimer’s disease
Vascular Aβ deposits of variable degree (Figure 3A, B, E,
and F) were detected in two- thirds (8 of 12) of the SAD8 antibodies. Freshly dissolved synthetic Aβ variants (2 μg each) were
imers and tetramers while (B) the monoclonal pan-Aβ antibody 4G8
Figure 3 Immunohistochemical staining pattern of Aβ5-X in cortex of sporadic AD human brain. Vascular Aβ5-x immunoreactivity (A, E, F)
was detected in the majority of the SAD cases analyzed in hippocampus (A) and cerebral cortex (E), whereas extracellular Aβ5-x-positive deposits
(C, G, H) were less abundant in both brain areas (C, D). The pan-Aβ antibody 24311 (B, D) demonstrates cerebral amyloid angiopathy (CAA) and
plaque load (arrows). The same cortical region stained in a parallel section with the AB5-3 antibody (F, H) binds preferentially to blood vessels
presenting CAA and barely recognizes plaques. Scale bar: 50 μm.
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using immunohistochemical analysis with the AB5-3
antibody. The extent of vascular immunoreactivity cor-
responded to the severity of CAA, which was assessed
using the pan-Aβ antibody 4G8 (Table 1). Extracellular
Aβ5-x-immunoreactivity was observed in 8 of 12 SAD
cases (Figure 3C, D, G, and H) and in 4 control cases.
Although plaque pathology and vascular deposits were
present in equal number of SAD cases, vascular immu-
noreactivity appeared stronger than the parenchymal
staining, probably due to a higher abundance of Aβ5-x in
vessels (Figure 3A, E and F). Using the 4G8 pan-Aβ
antibody, all subjects were proven to harbor a consider-
able extracellular plaque load with most of them (10 of
12) showing CAA in addition (Table 1). Consequently,
extracellular Aβ5-x isoforms were detected in 66% of
the subjects affected with plaque pathology and vascular
Aβ5-x immunoreactivity in 83% of the subjects affected
with CAA. Both diffuse and dense core plaques were
positive.
Aβ5-x in familial AD
Samples from five different subjects carrying different
autosomal dominant mutations, either in the APP or PS1
gene, were probed with the AB5-3 antibody. All familial
cases analyzed in the present study showed prominent vas-
cular and extracellular Aβ5-x-immunoreactivity. Two cases
harbored APP pathogenic mutations, either located at
codon 693 within the Aβ region of APP (E693G APP)
known as the Arctic mutation or a double mutation at co-
dons 670 and 671 close to the β-secretase cleavage site
(KM670/671NL APP) known as the Swedish mutation. On
one hand, the case carrying the Arctic mutation showedstrong vascular Aβ5-x-immunoreactivity and abundant
extracellular plaque deposits. On the other hand, brain
sections obtained from the subject carrying the Swedish
mutation presented a slightly stronger Aβ5-x-signal in the
vasculature and less Aβ5-x-immunoreactivity in plaques
(Figure 4). Both cases were compared to adjacent sections
stained with the 4G8 pan-Aβ antibody which demon-
strated abundant extracellular plaque pathology and CAA.
The cases harboring the PS1 mutation with the exon 9
deletion also showed abundant vascular staining and less
pronounced in plaques.
Both diffuse and dense core plaques were positive.Aβ5-x in mouse models of AD
The present report provides the first immunohistochem-
ical analysis of Aβ5-x in transgenic mouse models of AD.
We analyzed three different transgenic lines, namely
APP/PS1KI, 5XFAD and 3xTg (Table 2), which express
different combinations of human mutant APP, PS1 and
Tau. All of the mouse models showed Aβ5-x–positive
amyloid plaques to a different extent but none of them
revealed Aβ5-x–positive vascular deposits as expected
(Figures 5 and 6). Brain sections of the 3xTg mice (18-
month-old) showed amyloid deposits localized only in
the subiculum of the hippocampus and the medulla
(Figure 5E and J). Moreover, abundant Aβ5−X positive
plaques were observed in cortex, hippocampus, thal-
amus and piriform cortex in 10-month-old APP/PS1KI
and 12-month-old 5XFAD mice (Figure 5B, E, C and
F). Interestingly, the Aβ5-x peptides seemed to be not
very abundant and were mostly restricted to the core of
plaques (Figure 6).
Figure 4 Immunohistochemical staining pattern of Aβ5-x in cortex of familial AD human brain. Vascular and parenchymal Aβ5-x-positive
deposits were detected in parallel sections obtained from FAD cases including subjects with the Arctic (A) and Swedish mutations (C) in contrast
to abundant 4G8-immuoreactivity in both cases (B, D). Sections of a PS1ΔE9 mutation carrier probed with the AB5-3 antibody (E) showed equal
or higher vascular Aβ5-x-immunoreactivity compared to Aβ42 (F) whereas the Aβ5-x-parenchymal deposits were detected with lower intensity.
Scale bar: 200 μm.
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present early in the pathology, we used young APP/PS1KI
(2-month-old) and homozygous 5XFAD (1.5-month-old)
brain sections immunostained with the AB5-3 as both
models harbor abundant intraneuronal Aβ in contrast to
young 3xTg mice, which accumulate mostly APP [24,25].
No intracellular Aβ5−X was evident, while the 24311 pan-
Aβ antibody consistently showed intraneuronal aggrega-
tions in both mouse models. (Figure 7). Therefore, Aβ5−X
is not an early marker for neurodegeneration as it was only
present in extracellular amyloid deposits.
Both diffuse and dense core plaques were positive. As
it is known that neither 5XFAD, nor APP/PS1KI or 3xTgTable 2 Transgenic AD-like mouse models in which Aβ5-x dep
Mouse model AβPP PS1 Tau Pro
APP/PS1KI Swe, Lon M233T, L235P - Thy1 (APP)
5XFAD Swe, Flo, Lon M146L, L286V - Thy1 (A
3xTg Swe M146V P301L Thy1 (APP, Ta
Abbreviations: Swe Swedish, Flo Florida, Lon London, m age in months, C Cortex, Hipdevelops CAA, we could not find any blood vessels
stained with the Aβ antibodies used.
Discussion
Nowadays it is evident that a great heterogeneity of Aβ
species exist that are deposited in AD brains including the
full-length peptides, Aβ1–40 and Aβ1–42, and different C-
and N- truncated isoforms (for example [26-28]). Espe-
cially N-truncated Aβ peptides experienced a renaissance
in the last decade with the development of new transgenic
mouse models and novel Aβ N-terminal specific antibodies
for AD research [13,23]. N-truncated Aβx–42 species have
attracted much attention triggering the accumulation ofosition has been analyzed
moter Age Aβ5-x plaques Ref. Affected regions
PS1 knock-in 10 m ++ [20] C, Hip, Th, PiC
PP, PS1) 12 m ++ [21] C, Hip, Th, PiC
u) PS1 knock-in 18 m + [19] Hip
hippocampus, Th thalamus, PiC piriform cortex.
Figure 5 Immunohistochemical staining pattern of Aβ5-x in aged APP/PS1KI, 5XFAD and 3xTg transgenic mice. Parenchymal Aβ5-x
extracellular deposits were detected with the AB5-3 polyclonal antibody in the APP/PS1K1 (A-D), 5XFAD (F-I) and 3xTg on hippocampus (E) and
medulla (J). Larger regions were affected with plaques on hippocampus (A, F), cortex (B, G), thalamus (C, H) and piriform cortex (D, I) in the first
two mouse models. Scale bar: 50 μm.
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first to show a selective and drastic increase of these spe-
cies triggered by the mutation V715M APP770 in the APP
gene, postulating that all Aβx–42 variants are main factors
driving AD pathology.
The earliest evidence however for N-truncated pep-
tides was observed by Masters et al. [30] demonstrating
that Aβ peptides starting with phenylalanine at position
4 are main components of amyloid plaques. Aβ4–42 has
been suggested to play an important role in the disease
since it is deposited in early stages of the neuropathologyFigure 6 Analysis of consecutive sections of AD mouse models using
detected in hippocampal brain sections of the 3xTg (A, D), 5XFAD (B, E) a
antibody and the 24311 pan-Aβ antibody. Parallel sections reveal Aβ5-x imm
same amyloid plaque detected by the two different antibodies). Scale bar:before other isoforms appear [31]. On the other hand, an-
other prominent N-truncated variant, AβpE3–42, was also
suggested as a key player because of its limited degradation
and remarkable stability [32]. It is becoming more and
more accepted that the most prevalent Aβ variants present
in the brain regions affected by the disease are mainly the
42 ending variants Aβ1–42, AβpE3–42 and Aβ4–42 (for ex-
ample [26,28,33]). These Aβ variants, particularly Aβ4–42
and AβpE3–42, are considered to be the most toxic due to
their biochemical propensities to rapidly form stable oligo-
mers [23].the AB5-3 and 24311 antibodies. Extracellular plaques were
nd the APP/PS1K1 (C, F) mouse models with the AB5-3 polyclonal
unoreactivity localized in the core of the plaques (arrows point to the
50 μm.
Figure 7 Young 5XFAD and APP/PS1K1 mice do not present intraneuronal Aβ5-x deposits. No intraneuronal Aβ5-x deposits were found in
cortical brain sections of 1.5-month-old 5XFAD homozygous mice (A), as well as in hippocampal (C) and cortical sections of 2-month-old APP/
PS1K1mice (E). Parallel sections probed with the 24311 pan-Aβ antibody demonstrated the presence of intraneuronal Aβ immunoreactivity in
both AD transgenic mouse models (small arrows: B, D, F). Abundant amyloid plaques were detected with both antibodies in young APP/PS1K1
mice (large arrows: C-F). Scale bar: A-D = 50 μm; E, F = 100 μm.
Guzmán et al. Molecular Neurodegeneration 2014, 9:13 Page 8 of 11
http://www.molecularneurodegeneration.com/content/9/1/13Despite the above mentioned importance of N-
truncated peptides for AD, little is known about Aβ5–X. It
has been recognized to be present in Aβ deposits of SAD
patients [34]. Using mass spectrometry and Western blot
of SAD cases and mass spectrometry of SAD and FAD
cases (M146V PS1 or KM670/671NL APP), Aβ5–40/42 was
one of the detected N-truncated species [26-28,31]. Re-
garding transgenic mouse lines, mass spectrometry of
immunoprecipitated Aβ peptides have also provided evi-
dence of the presence of Aβ5–42. Casas et al. [20] reported
Aβ5–42 deposition in the APP/PS1KI mice. Our group de-
tected Aβ5–42 peptides in the 5XFAD mouse model [35].
The current report aims to provide a better understand-
ing of a possible contribution of Aβ5–X in three different
transgenic amyloid mouse models, SAD and FAD cases.
Previous papers reported on a rabbit polyclonal [34] and a
mouse monoclonal antibody [14] specific to the N-terminal
end of Aβ5–40/42, which bind to the epitope Aβ5–12 (NH2-
RHDSGYEVC-COOH). We have generated a rabbit poly-
clonal antibody, which specifically binds to Aβ5–x as shownby dot blot and Western blot. The AB5-3 strongly detects
Aβ5–42 low molecular weight oligomers showing its specifi-
city for peptides starting with an arginine at position 5,
while other Aβ variants starting at position 1, 3 (pyrogluta-
mate) and 4 did not cross-react. While the polyclonal anti-
body AB5-3 reacted specifically with the free N-terminus of
Aβ5–42, we cannot exclude that it also may recognize Aβ6-X
variants.
In agreement with the observations of the previously
published polyclonal antibody [34], we detected parenchy-
mal and vascular deposits in SAD. Vascular Aβ5-x seems
to be present in most (80%) of the cases. Confirming pub-
lished observations [34], the vascular Aβ5-x deposits often
showed a stronger signal than aggregation in plaques of
SAD cases. Immunostainings with the AB5-3 confirmed
the presence of the Aβ5–x in extracellular deposits, how-
ever at a minor degree corroborating previous studies.
For the first time we present evidence that Aβ5-x immu-
noreactivity is abundant in extracellular plaques and vas-
cular deposits in different FAD cases. The cases studied
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mutations, as well as the PS1 delta exon 9 mutation. Dif-
ferent patterns of Aβ5–X aggregation were found among
the different FAD cases. Previous data obtained from pa-
tients carrying the APP Arctic mutation reported ring-like
plaques with Aβ peptides showing an accentuation of the
contour and negative or weakly stained centers [36]. Ac-
cording to Nilsberth et al. [16] the Arctic mutation leads
to an increase of Aβ protofibril formation, however the
underlying molecular mechanism is still unknown.
Intraneuronal Aβ is a major risk factor in AD path-
ology triggering neuron loss [37-40]. During the last
years, intraneuronal accumulation has been reported in
several mouse models including APPSDLPS1M146L [41],
APPSLPS1M146L [42], Tg2576 [43], 3xTg-AD [19], APPArc
[44,45], 5XFAD [21], APPT714I [46], APPSL/PS1M146L [47],
APP/PS1KI [20,48,49], TBA2 mice expressing pyrogluta-
mate modified Aβ3–42 [50] and in Tg4-42 expressing Aβ4–42
[23]. Furthermore, early intraneuronal Aβ accumulations
have been detected in the homozygous 5XFAD mouse
model at 1.5 months of age immediately preceding extracel-
lular plaque deposition occurring at the age of 2 months
[51]. Abundant intraneuronal Aβ has been demonstrated to
correlate with a reduced number of neurons irrespectively
of the extracellular Aβ aggregates in APP/PS1KI and in
5XFAD mice [40].
Using the AB5-3 no Aβ5-x intraneuronal immunoreac-
tivity was found in young mice APP/PS1KI and in 5XFAD
mice. This observation indicates that Aβ5-x may not con-
tribute to trigger neuronal degeneration and appears late
in AD pathology. Despite the fact that Aβ5–x is a scarce
variant in AD brains it was present in almost all sporadic
cases and in virtually all the familial AD cases tested with
a different degree regarding CAA and plaque deposition.
Contrasting previous findings with abundant intraneuro-
nal N-truncated Aβ4-x in homozygous 5XFAD mice [51],
Aβ5–x appeared late in the amyloid cascade as there was
no intraneuronal staining in young APP/PS1KI and homo-
zygous 5XFAD mice. A variety of different N-truncated
Aβ peptides besides Aβ5-x (Arg-5) have been identified in
AD brains including Ala-2, pyroglutamylated Glu-3, Phe-
4, His-6, Asp-7, Ser-8, Gly-9, Tyr-10 and pyroglutamylated
Glu-11 [26-31,52-55]. We cannot rule out however that
the polyclonal antibody AB5-3 may cross-react with other
N-truncated Aβ variants not studied here that may be
more prevalent than Arg-5 in amyloid plaques.
Conclusions
Although a considerable amount of Aβ5-x can be found in
transgenic AD mouse models, SAD and FAD cases, no
intracellular Aβ5-x deposits of these peptides were found
neither in the different mouse lines nor in the human
cases. Due to the lack of intracellular Aβ5-x, it is unlikely
to participate in early events of the AD pathology. Thisindicates that Aβ5-x might participate in extracellular pre-
cipitation of Aβ peptides within plaques and is therefore
not likely to be involved in triggering neuronal loss.
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